Health position paper and redox perspectives - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases

dc.contributor.authorCuadrado, Antonio
dc.contributor.authorCazalla, Eduardo
dc.contributor.authorBach, Anders
dc.contributor.authorBathish, Boushra
dc.contributor.authorNaidu, Sharadha Dayalan
dc.contributor.authorDeNicola, Gina M.
dc.contributor.authorDinkova-Kostova, Albena T.
dc.contributor.authorFernández-Ginés, Raquel
dc.contributor.authorGrochot-Przeczek, Anna
dc.contributor.authorHayes, John D.
dc.contributor.authorKensler, Thomas W.
dc.contributor.authorLeón, Rafael
dc.contributor.authorLiby, Karen T.
dc.contributor.authorLópez, Manuela G.
dc.contributor.authorManda, Gina
dc.contributor.authorShivakumar, Akshatha Kalavathi
dc.contributor.authorHakomäki, Henriikka
dc.contributor.authorMoerland, Jessica A.
dc.contributor.authorMotohashi, Hozumi
dc.contributor.authorRojo, Ana I.
dc.contributor.authorSykiotis, Gerasimos P.
dc.contributor.authorTaguchi, Keiko
dc.contributor.authorValverde, Ángela M.
dc.contributor.authorYamamoto, Masayuki
dc.contributor.authorLevonen, Anna-Liisa
dc.contributor.departmentMedicine, School of Medicine
dc.date.accessioned2025-05-13T13:04:13Z
dc.date.available2025-05-13T13:04:13Z
dc.date.issued2025
dc.description.abstractNuclear factor erythroid 2-related factor 2 (NRF2) is a redox-activated transcription factor regulating cellular defense against oxidative stress, thereby playing a pivotal role in maintaining cellular homeostasis. Its dysregulation is implicated in the progression of a wide array of human diseases, making NRF2 a compelling target for therapeutic interventions. However, challenges persist in drug discovery and safe targeting of NRF2, as unresolved questions remain especially regarding its context-specific role in diseases and off-target effects. This comprehensive review discusses the dualistic role of NRF2 in disease pathophysiology, covering its protective and/or destructive roles in autoimmune, respiratory, cardiovascular, and metabolic diseases, as well as diseases of the digestive system and cancer. Additionally, we also review the development of drugs that either activate or inhibit NRF2, discuss main barriers in translating NRF2-based therapies from bench to bedside, and consider the ways to monitor NRF2 activation in vivo.
dc.eprint.versionFinal published version
dc.identifier.citationCuadrado A, Cazalla E, Bach A, et al. Health position paper and redox perspectives - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases. Redox Biol. 2025;81:103569. doi:10.1016/j.redox.2025.103569
dc.identifier.urihttps://hdl.handle.net/1805/48039
dc.language.isoen_US
dc.publisherElsevier
dc.relation.isversionof10.1016/j.redox.2025.103569
dc.relation.journalRedox Biology
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourcePMC
dc.subjectDrug repurposing
dc.subjectGSK-3
dc.subjectKEAP1
dc.subjectNRF2 diseasome
dc.subjectβ-TrCP
dc.titleHealth position paper and redox perspectives - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Cuadrado2025Health-CCBYNCND.pdf
Size:
10.46 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: